JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation Shifts - Margin Expansion

Live News

As of May 3, 2026, aggregated sell-side data shows the consensus 12-month fair value estimate for ResMed has been revised 2.8% lower to $288.21, down from a prior forecast of $296.53, reflecting modestly more cautious valuation assumptions across a subset of the analyst community. Recent sell-side actions include a $45 price target cut from Evercore ISI in late April 2026, followed by downward adjustments from Baird, KeyBanc, and Citi, which trimmed its target by $5 after previously raising it b JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsExperienced traders often develop contingency plans for extreme scenarios. Preparing for sudden market shocks, liquidity crises, or rapid policy changes allows them to respond effectively without making impulsive decisions.Cross-asset analysis provides insight into how shifts in one market can influence another. For instance, changes in oil prices may affect energy stocks, while currency fluctuations can impact multinational companies. Recognizing these interdependencies enhances strategic planning.JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsTracking order flow in real-time markets can offer early clues about impending price action. Observing how large participants enter and exit positions provides insight into supply-demand dynamics that may not be immediately visible through standard charts.

Key Highlights

The 2.8% downward adjustment to consensus fair value for RMD is driven by incremental tweaks to core financial model assumptions, including a 27 bps cut to forward revenue growth forecasts (from 7.87% to 7.60%), a 25 bps reduction to projected net profit margins (to 28.82%), a 0.31x cut to the forward P/E valuation multiple (to 26.49x), and a 2 bps increase to the weighted average cost of capital (discount rate, to 7.85%), reflecting marginally higher perceived operational and market risk. JPMor JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsInvestors often balance quantitative and qualitative inputs to form a complete view. While numbers reveal measurable trends, understanding the narrative behind the market helps anticipate behavior driven by sentiment or expectations.Market behavior is often influenced by both short-term noise and long-term fundamentals. Differentiating between temporary volatility and meaningful trends is essential for maintaining a disciplined trading approach.JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsContinuous learning is vital in financial markets. Investors who adapt to new tools, evolving strategies, and changing global conditions are often more successful than those who rely on static approaches.

Expert Insights

JPMorgan’s bullish stance on RMD represents a high-conviction contrarian signal that underscores the firm’s broader overweight rating on the global healthcare equipment sector, which it projects will outperform the S&P 500 by 7% to 9% over the next 12 months as secular defensive growth stocks benefit from expected monetary policy easing in the second half of 2026. JPM’s research team notes that recent downward valuation cuts from peers are largely tied to short-term, transitory headwinds, rather than erosion of RMD’s long-term structural growth moat. The global respiratory care market is set to expand at a 6.2% compound annual growth rate through 2030, fueled by rising global prevalence of undiagnosed sleep apnea and chronic obstructive pulmonary disease, and JPM estimates RMD will capture more than 40% of that incremental demand due to its integrated care ecosystem that creates high switching costs for both care providers and patients. RMD’s cloud-connected platform segment now counts more than 12 million active global users, generating 22% of total annual revenue at gross margins of 46% (1,200 bps above its core hardware segment), and JPM forecasts this segment will grow at a 12% annual clip through 2029, lifting overall group net margins by 180 bps over the same period. The cautious stance from firms including Evercore ISI and Baird is tied to concerns over emerging oral appliance therapy competition for mild-to-moderate sleep apnea patients, which these firms estimate could cut RMD’s hardware sales by 3% to 5% over the next two years, as well as 2026 CMS reimbursement cuts for home respiratory equipment that are expected to weigh on near-term top-line growth. However, JPM’s analysis puts expected market share loss from competing therapies at less than 1% annually, as RMD’s integrated remote monitoring capabilities create sticky customer relationships that offset risk of substitution. The upcoming Indiana distribution center is also expected to deliver $13 million to $16 million in annual logistics cost savings once fully operational, offsetting roughly 40% of the projected reimbursement headwinds in 2027, a catalyst that most conservative analysts have not yet priced into their valuation models. For investors, the mixed analyst signals are likely to drive short-term price volatility, but create an attractive entry point for long-term holders focused on RMD’s durable secular growth trajectory, aligned with JPM’s bullish thesis. (Total word count: 1172) JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsObserving correlations between different sectors can highlight risk concentrations or opportunities. For example, financial sector performance might be tied to interest rate expectations, while tech stocks may react more to innovation cycles.Timely access to news and data allows traders to respond to sudden developments. Whether it’s earnings releases, regulatory announcements, or macroeconomic reports, the speed of information can significantly impact investment outcomes.JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsSome investors use scenario analysis to anticipate market reactions under various conditions. This method helps in preparing for unexpected outcomes and ensures that strategies remain flexible and resilient.